PDF(Pubmed)
Abstract：
Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.
About 70% of newly diagnosed breast cancers belong to a specific subgroup called hormone receptor positive (HR+)/Human epidermal growth factor receptor 2 negative (HER2-). In cases with metastatic disease, doctors recommend a treatment approach combining drugs such as palbociclib along with hormonal therapy. Our review evaluates how palbociclib performs in patients in real-world practice situations, beyond clinical trial settings. We looked at two key measures: how long the cancer stays controlled (progression-free survival) and overall survival. The results from these real-world studies are discussed and compared to findings in clinical trials.
About 70% of newly diagnosed breast cancers belong to a specific subgroup called hormone receptor positive (HR+)/Human epidermal growth factor receptor 2 negative (HER2-). In cases with metastatic disease, doctors recommend a treatment approach combining drugs such as palbociclib along with hormonal therapy. Our review evaluates how palbociclib performs in patients in real-world practice situations, beyond clinical trial settings. We looked at two key measures: how long the cancer stays controlled (progression-free survival) and overall survival. The results from these real-world studies are discussed and compared to findings in clinical trials.
摘要：
大约70%的新诊断乳腺癌是HR+/HER2-亚型。对于HR+/HER2-转移性乳腺癌患者的治疗，目前的指南建议使用CDK4/6抑制剂(palbociclib，ribociclib或abemaciclib）与内分泌治疗相结合。在这篇综述中，我们评估了有关palbociclib在现实世界中的有效性的现有文献。在纳入的真实世界研究中以及与III期PALOMA试验相关的研究中，讨论并比较了无进展生存期和总生存期方面的生存结果。
大约70％的新诊断乳腺癌属于一个特定的亚组，称为激素受体阳性（HR）/人类表皮生长因子受体2阴性（HER2-）。在转移性疾病的病例中，医生建议将palbociclib等药物与激素治疗相结合的治疗方法。我们的综述评估了palbociclib在现实实践情况下在患者中的表现，超出临床试验设置。我们研究了两个关键指标：癌症保持控制的时间（无进展生存期）和总生存期。讨论了这些真实世界研究的结果，并将其与临床试验的结果进行了比较。
大约70％的新诊断乳腺癌属于一个特定的亚组，称为激素受体阳性（HR）/人类表皮生长因子受体2阴性（HER2-）。在转移性疾病的病例中，医生建议将palbociclib等药物与激素治疗相结合的治疗方法。我们的综述评估了palbociclib在现实实践情况下在患者中的表现，超出临床试验设置。我们研究了两个关键指标：癌症保持控制的时间（无进展生存期）和总生存期。讨论了这些真实世界研究的结果，并将其与临床试验的结果进行了比较。
